News Vogenx surpasses expectations with $81m IPO With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.
News Apnimed IPO raises $192m, as three other biotechs set terms Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.
News BlossomHill, Vogenx and Latigo reveal IPO plans Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, Vogenx, and Latigo - as 2026 heads for a record IPO haul.
News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon be offering some of the unapproved peptides subject to the FDA's enforcement discretion policy to its customers.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
